CLDX Celldex Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

CLDX [NASD]

Celldex Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.22	Insider Own	0.10%	Shs Outstand	39.28M	Perf Week	10.91%
Market Cap	863.91M	Forward P/E	-	EPS next Y	-1.46	Insider Trans	106.29%	Shs Float	29.28M	Perf Month	37.22%
Income	-48.30M	PEG	-	EPS next Q	-0.37	Inst Own	81.80%	Short Float	10.19%	Perf Quarter	95.77%
Sales	4.50M	P/S	191.98	EPS this Y	75.80%	Inst Trans	14.25%	Short Ratio	4.36	Perf Half Y	714.61%
Book/sh	5.86	P/B	3.71	EPS next Y	17.50%	ROA	-25.70%	Target Price	26.33	Perf Year	853.95%
Cash/sh	5.03	P/C	4.33	EPS next 5Y	-	ROE	-29.90%	52W Range	1.50 - 22.79	Perf YTD	875.34%
Dividend	-	P/FCF	-	EPS past 5Y	29.30%	ROI	-58.50%	52W High	-4.56%	Beta	2.96
Dividend %	-	Quick Ratio	16.60	Sales past 5Y	-0.10%	Gross Margin	-	52W Low	1350.00%	ATR	1.35
Employees	127	Current Ratio	16.60	Sales Q/Q	40.00%	Oper. Margin	-	RSI (14)	72.38	Volatility	6.59% 7.59%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	51.50%	Profit Margin	-	Rel Volume	0.73	Prev Close	22.25
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	684.66K	Price	21.75
Recom	2.00	SMA20	16.99%	SMA50	31.63%	SMA200	143.77%	Volume	497,716	Change	-2.25%

Feb-21-20

Initiated

Cantor Fitzgerald

Overweight

Aug-01-17

Resumed

H.C. Wainwright

Buy

$10

Nov-07-16

Initiated

Aegis Capital

Buy

Mar-08-16

Downgrade

Jefferies

Buy → Hold

Mar-07-16

Downgrade

Wedbush

Outperform → Neutral

Mar-07-16

Downgrade

Leerink Partners

Outperform → Mkt Perform

Mar-07-16

Downgrade

Guggenheim

Buy → Neutral

Mar-01-16

Initiated

H.C. Wainwright

Buy

$25

Aug-11-15

Reiterated

ROTH Capital

Buy

$43 → $39

Aug-11-15

Reiterated

Oppenheimer

Outperform

$45 → $42

Aug-11-15

Reiterated

Brean Capital

Buy

$35 → $31

Jun-02-15

Reiterated

WBB Securities

Strong Buy

$30 → $40

Nov-17-14

Reiterated

ROTH Capital

Buy

$40 → $43

Mar-04-14

Reiterated

Oppenheimer

Outperform

$40 → $36

Jul-08-13

Reiterated

Cantor Fitzgerald

Buy

$16 → $24

Mar-08-13

Reiterated

Cantor Fitzgerald

Buy

$13 → $16

Feb-26-13

Reiterated

Oppenheimer

Outperform

$10 → $13

Jan-10-13

Reiterated

Cantor Fitzgerald

Buy

$9 → $13

Oct-02-12

Reiterated

Oppenheimer

Outperform

$6 → $8

Sep-14-12

Reiterated

Cantor Fitzgerald

Buy

$7 → $9

Nov-09-20 08:01AM	Celldex Presents Data from Oncology Portfolio at SITC 2020 GlobeNewswire
Nov-05-20 05:55PM	Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Celldex Provides Corporate Update and Reports Third Quarter 2020 Results GlobeNewswire
Nov-03-20 12:31PM	Will Celldex Therapeutics (CLDX) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-15-20 08:14PM	2 Biotech Stocks That Keep on Climbing Motley Fool -5.45%
Oct-14-20 11:32AM	Celldex Initiates Early-Stage Antibody Study for Skin Disorder Zacks
Oct-13-20 08:01AM	Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria GlobeNewswire
Oct-06-20 06:09PM	Hedge Funds Have Never Been This Bullish On Celldex Therapeutics, Inc. (CLDX) Insider Monkey +19.47%
Sep-29-20 08:58AM	Is the Options Market Predicting a Spike in Celldex Therapeutics (CLDX) Stock? Zacks
Sep-10-20 04:01PM	Celldex Therapeutics to Present at Upcoming Healthcare Conferences GlobeNewswire
Aug-25-20 01:25PM	The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics Zacks
Aug-24-20 08:01AM	Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors GlobeNewswire
Aug-06-20 04:01PM	Celldex Provides Corporate Update and Reports Second Quarter 2020 Results GlobeNewswire
Aug-03-20 08:01AM	Celldex to Report Second Quarter 2020 Financial Results and Host Corporate Update Call GlobeNewswire +7.87%
Jul-29-20 12:33PM	Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -13.30%
Jul-09-20 11:01AM	Top Ranked Momentum Stocks to Buy for July 9th Zacks
Jul-08-20 07:32AM	Celldex Therapeutics, Inc. (CLDX) Shares March Higher, Can It Continue? Zacks
Jun-18-20 10:31AM	Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jun-15-20 10:35PM	Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock GlobeNewswire +37.31%
04:01PM	Celldex Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Jun-12-20 10:39AM	Insider Buys Celldex Therapeutics's Stock Benzinga -10.91%
Jun-11-20 10:39AM	Insider Buys Celldex Therapeutics' Shares Benzinga +82.40%
08:46AM	Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options Zacks
Jun-09-20 07:46AM	The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates Benzinga
Jun-06-20 03:01AM	Celldexs KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptasean Indicator of Mast Cell Burdenand a Favorable Safety Profile GlobeNewswire
May-28-20 03:22PM	Hedge Funds Are Dumping Celldex Therapeutics, Inc. (CLDX) Insider Monkey
May-25-20 11:30AM	Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year? Zacks
May-06-20 04:01PM	Celldex Provides Corporate Update and Reports First Quarter 2020 Results GlobeNewswire
11:30AM	Is Celldex Therapeutics, Inc.(CLDX) Stock Outpacing Its Medical Peers This Year? Zacks
08:01AM	Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020 GlobeNewswire
Apr-24-20 08:56AM	Celldex (CLDX) Soars: Stock Adds 10% in Session Zacks
Apr-14-20 08:37AM	Moleculin (MBRX) Looks Good: Stock Adds 5.3% in Session Zacks
Apr-06-20 08:53AM	UroGen (URGN) Looks Good: Stock Adds 8.1% in Session Zacks
Mar-26-20 04:01PM	Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results GlobeNewswire
Mar-03-20 08:01AM	Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program GlobeNewswire
Dec-23-19 10:26AM	Is Celldex Therapeutics, Inc. (CLDX) A Good Stock To Buy? Insider Monkey
Dec-12-19 11:30AM	Celldex (CLDX) Down 3.9% Since Last Earnings Report: Can It Rebound? Zacks
Nov-18-19 08:01AM	Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159 GlobeNewswire -5.95%
Nov-14-19 09:44AM	Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss Zacks
Nov-12-19 09:25AM	Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:01AM	Celldex Provides Corporate Update and Reports Third Quarter 2019 Results GlobeNewswire
Nov-11-19 08:01AM	Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs GlobeNewswire
Nov-08-19 07:30AM	CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study GlobeNewswire -9.16%
Oct-30-19 10:33AM	Will Celldex Therapeutics (CLDX) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-02-19 08:01AM	Celldex Therapeutics Announces Upcoming Data Presentations GlobeNewswire
Sep-30-19 04:01PM	Celldex Therapeutics to Present at the Cantor Global Healthcare Conference GlobeNewswire
Sep-06-19 12:11PM	Edited Transcript of CLDX earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
09:31AM	Why Is Celldex (CLDX) Down 2.3% Since Last Earnings Report? Zacks
Aug-14-19 09:10AM	Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD Zacks
Aug-13-19 11:53AM	Mallinckrodt Enrolls First Patient in Liver Disease Study Zacks +5.21%
09:50AM	Regeneron Ebola Treatment Shows Promise, Study Stopped Early Zacks
Aug-08-19 04:23PM	Celldex Therapeutics Inc (CLDX) Q2 2019 Earnings Call Transcript Motley Fool
10:54AM	Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss Zacks
06:00AM	Celldex Therapeutics Keeps Up Its Penny-Pinching and Pipeline Progress Motley Fool
Aug-07-19 06:45PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates Zacks
Jul-31-19 04:01PM	Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call GlobeNewswire
Jun-24-19 08:01AM	Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer GlobeNewswire
Jun-06-19 09:31AM	Why Is Celldex (CLDX) Down 29.2% Since Last Earnings Report? Zacks
Jun-04-19 10:26AM	Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down Zacks
07:45AM	The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer Benzinga
Jun-01-19 02:15PM	Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma GlobeNewswire
May-26-19 05:03PM	The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-14-19 12:36PM	Wall Street Sees 3 Falling Knives Rebounding Within 52 Weeks GuruFocus.com
May-08-19 07:00AM	Celldex Therapeutics Continues to Stretch Out Its Cash and Advance Its Pipeline Motley Fool
May-07-19 06:15PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates Zacks
05:09PM	Celldex: 1Q Earnings Snapshot Associated Press
04:01PM	Celldex Provides Corporate Update and Reports First Quarter 2019 Results GlobeNewswire
May-02-19 10:32AM	Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-06-19 09:30AM	Celldex (CLDX) Down 5.7% Since Last Earnings Report: Can It Rebound? Zacks
Apr-02-19 08:00AM	Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire -11.39%
Apr-01-19 01:00PM	Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire
Mar-20-19 09:30AM	Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year? Zacks
Mar-13-19 01:19PM	Edited Transcript of CLDX earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-08-19 11:04AM	Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat Zacks +10.87%
07:45AM	Celldex Therapeutics' Cost-Cutting and Reverse Stock Split Help Keep It Rolling Motley Fool
Mar-07-19 07:44PM	Celldex Therapeutics, Inc (CLDX) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM	Celldex Provides Corporate Update and Reports Full Year 2018 Results GlobeNewswire
07:48AM	Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO Benzinga
Feb-22-19 05:50PM	Celldex Therapeutics (CLDX) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-20-19 08:25AM	Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cubic Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-14-19 10:45AM	The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna Zacks -6.51%
Feb-13-19 08:36AM	5 Tiny Biotech Stocks With Superb Growth Potential Zacks +10.82%
Feb-11-19 12:26PM	The Celldex Reverse Stock Split: What Investors Need To Know Benzinga -19.03%
09:55AM	Biotech Stocks To Watch ACCESSWIRE
Feb-08-19 11:45AM	Celldex Therapeutics Announces Reverse Stock Split GlobeNewswire -31.17%
Feb-05-19 09:20AM	4 Healthcare Stocks The Market is Watching on Tuesday (2/5/19) ACCESSWIRE -16.04%
08:30AM	Biotech Stocks to Watch ACCESSWIRE
Feb-04-19 02:35PM	These 4 Tech Stocks Could Set February Highs ACCESSWIRE +19.35%
Jan-29-19 08:30AM	Cannabis and Biotech Stocks that Could Explode ACCESSWIRE
Jan-23-19 08:30AM	Best Ways to Play Biotech Rally ACCESSWIRE
Jan-21-19 08:30AM	A Biotech Play You Can't Afford To Miss ACCESSWIRE
Dec-21-18 08:15PM	Here's Why Celldex Therapeutics Sank on Friday Motley Fool -13.08%
Dec-10-18 12:24PM	Why Celldex Therapeutics Is Jumping Today Motley Fool +6.61%
Nov-26-18 08:35AM	Analysis: Positioning to Benefit within Celldex Therapeutics, InnSuites Hospitality Trust, Keryx Biopharmaceuticals, EMX Royalty, FTE Networks, and Xinyuan Real Estate Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-10-18 08:01AM	Celldex Presents Emerging MerTK Antibody Program at the Society for Immunotherapy of Cancers 33rd Annual Meeting GlobeNewswire
Nov-09-18 08:12AM	Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss Zacks
08:01AM	Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancers 33rd Annual Meeting GlobeNewswire
Nov-08-18 05:48PM	Here's Why Celldex Therapeutics, Inc. Surged on Thursday Motley Fool +12.79%
08:45AM	Celldex Therapeutics Inc. Chugs Along in the 3rd Quarter Despite Challenges Motley Fool
Nov-07-18 06:55PM	Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates Zacks

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young Diane C.	SVP, Chief Medical Officer	Jun 11	Buy	4.73	2,115	10,004	2,115	Jun 12 07:55 AM
Cavanaugh Sarah	SVP of Corp Affairs & Admin.	Jun 10	Buy	4.83	1,050	5,072	1,367	Jun 11 07:54 AM
Heath-Chiozzi Margo	SVP of Regulatory Affairs	Jun 09	Buy	3.01	1,000	3,005	1,000	Jun 10 07:55 AM
KELER TIBOR	Executive VP & CSO	Jun 09	Buy	2.99	5,000	14,954	7,357	Jun 10 07:54 AM
MARINO JAMES J	Director	Jun 09	Buy	3.00	8,305	24,915	12,704	Jun 10 07:54 AM
Martin Samuel Bates	SVP and CFO	Jun 09	Buy	3.05	9,750	29,738	10,735	Jun 10 07:55 AM
Marucci Anthony S	President & CEO	Jun 09	Buy	3.06	15,000	45,900	19,438	Jun 10 07:54 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience